Emcure Pharmaceuticals Limited has informed the Exchange regarding Cessation of Mr Anil Kothiyal as Other of the company w.e.f. Jun 06, 2025.
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emcure Pharmaceuticals has informed the exchanges that Mr. Anil Kothiyal, President – India Sales & Marketing and Senior Management Personnel of the company, has resigned with effect from the close of business hours on June 06, 2025. The resignation is stated to be on account of personal reasons, as mentioned in his letter dated June 03, 2025 addressed to Executive Director Ms. Namita Thapar. The company has filed this under Regulation 30 of SEBI LODR with the required Annexure A disclosures (reason, cessation date, and that no new appointment is being made via this filing). No successor has been named in this filing, and the company has disclosed the resignation letter as Annexure B.
Loss of a senior leader heading India sales & marketing, which is the company's core domestic business — investors should watch for a timely replacement announcement to ensure business continuity. The resignation is for personal reasons, so no immediate red flag, but leadership gaps in revenue-generating functions can affect short-term execution.